Experimental MDS drug combo shows promise but study halted early
NCT ID NCT03946670
First seen Nov 26, 2025 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tested adding an experimental drug (MBG453) to standard chemotherapy for people with a serious bone marrow disorder called myelodysplastic syndrome (MDS). The goal was to see if the combination could improve remission rates and delay disease progression. The study included 127 adults with intermediate to very high-risk MDS who could not have a stem cell transplant. The study was terminated early, but the results may still provide valuable information about treating this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City Of Hope National Med Center
Duarte, California, 91010, United States
-
City of Hope National Medical Center Medical Oncology & Therapeutic
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Novartis Investigative Site
Vienna, 1140, Austria
-
Novartis Investigative Site
Brasschaat, 2930, Belgium
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Québec, Quebec, G1J 1Z4, Canada
-
Novartis Investigative Site
Brno, 625 00, Czechia
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Leipzig, Saxony, 04103, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Alexandroupoli, 681 00, Greece
-
Novartis Investigative Site
Larissa, 411 10, Greece
-
Novartis Investigative Site
Pátrai, 265 04, Greece
-
Novartis Investigative Site
Hong Kong, Hong Kong
-
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, 4032, Hungary
-
Novartis Investigative Site
Nyíregyháza, 4400, Hungary
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Rozzano, MI, 20089, Italy
-
Novartis Investigative Site
Reggio Calabria, RC, 89124, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Fukuoka, Fukuoka, 812-8582, Japan
-
Novartis Investigative Site
Fukushima, Fukushima, 960 1295, Japan
-
Novartis Investigative Site
Isehara, Kanagawa, 259-1193, Japan
-
Novartis Investigative Site
Kumamoto, Kumamoto, 860-0008, Japan
-
Novartis Investigative Site
Sendai, Miyagi, 983 8520, Japan
-
Novartis Investigative Site
Nagasaki, Nagasaki, 852-8501, Japan
-
Novartis Investigative Site
Bunkyo Ku, Tokyo, 113-8677, Japan
-
Novartis Investigative Site
Gifu, 500 8513, Japan
-
Novartis Investigative Site
Osaka, 545-8586, Japan
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Seoul, 06351, South Korea
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Santander, Cantabria, 39008, Spain
-
Novartis Investigative Site
Málaga, 29010, Spain
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Samsun, Atakum, 55200, Turkey (Türkiye)
-
Novartis Investigative Site
Köseköy, Kocaeli, 41380, Turkey (Türkiye)
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
Ohio State Comprehensive Cancer Center James Cancer Hospital
Columbus, Ohio, 73210, United States
-
The Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Yale University School Of Medicine
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.